Skip to main content
Evidence Based Longevity (EBL)Check what I take
← All protocols
C

Protocol · graded by use, four uses

Ornish Lifestyle Medicine

Graded on: cardiac events and coronary artery narrowing in coronary heart disease.

Grade C: human trials exist, but they are small, mixed or not yet repeated. This is not a finding that it does not work. How to read a grade →

Compare this record with another, side by side →

At a glance

In plain words

This program pairs a very low-fat vegetarian diet with daily exercise, stress management and group support. In one small trial of people with heart disease, artery narrowing slowed or improved, and heart problems were less common over 5 years. In one small trial of people with early Alzheimer's disease, memory and thinking scores did better than in a group that waited. In one small trial of men with early prostate cancer, PSA dipped slightly. The program's own team ran all three, and no other team has repeated them. The trials tested everything together, so nobody knows how much came from the food.

The letter, taken apart
What was measured
Heart problems (heart attacks, artery procedures, heart-related hospital stays and deaths) over 5 years in people with heart disease.
How big
Heart problems were 2.47 times as frequent in the usual-care group as on the program over 5 years, counting repeat problems in the same person.Read from the summary of PMID PubMed ID: the permanent number the US National Library of Medicine gives a published paper. Each one links to that paper's record on PubMed. 9863851.
Who it applies to
48 adults with moderate to severe coronary heart disease, 35 of whom completed the 5-year scans. The trial was run by the program's developers and has not been repeated.
Safety
No harm specific to the program is on file for this record. That is an absence of evidence, not a finding of safety. People with heart disease exercised under medical oversight in the trials.
The record in one view
Compared with
Usual care from their own doctors.
Certainty
Grade C, resting on: Small randomized controlled trials People are assigned to the treatment or a comparison by chance, so the groups differ only in what they received. It is the design that can show cause and effect. of the whole program, each run by the program's developers and none independently repeated.
What would change this grade
Could rise to A with: Randomized trial of the full program against usual care or standard cardiac rehabilitation, run by at least two groups independent of the program's developers, with events adjudicated blind to group. Who: Adults with coronary heart disease, at least 500 per arm. Measured: Myocardial infarction, stroke and cardiovascular death, counted per patient. Length: At least 3 years.
Cost
No price recorded yet.
Sources
9 studies cited on this record, listed under Sources.
For clinicians
A one-page summary of this record that prints with a clinician's name and practice, folds to a plain-language patient handout, and gives a chart note to paste into the patient record: Printable summary and chart note.

The C is shared by three of the four uses graded on this record, each on its own evidence. The other one carries its own letter.

Graded by use

This record carries a separate letter for each thing it has been measured on. The headline grade is the best of them, and it does not transfer to the others.

CHard clinical endpoint Coronary narrowing and cardiac events in coronary heart disease

This is the use the Ornish Reversal Program is built on. The Lifestyle Heart Trial (Ornish et al., Lancet, 1990; PMID 1973470; JAMA, 1998; PMID 9863851) randomized 48 patients; at 5 years diameter stenosis improved 3.1 percentage points on the program and worsened 11.8 in controls, with 25 cardiac events in 28 program patients against 45 in 20 controls (risk ratio 2.47 for controls). Heart perfusion scans in the same patients pointed the same way (Gould et al., JAMA, 1995; PMID 7674504), which is the same trial, not a replication The same finding reproduced by a separate research group. A result seen once can be chance or bias; a replicated one is harder to explain away.. The only independent randomized trial of the program, against standard cardiac rehabilitation in 93 patients (Aldana et al., Am J Health Promot, 2007; PMID 17674638), found no change in carotid intima-media thickness, a different artery and an active comparator. One small unreplicated trial: C.

CBlinded clinician rating Cognition and function in mild cognitive impairment or early Alzheimer's disease

Ornish et al. (Alzheimers Res Ther, 2024; PMID 38849944): 51 patients aged 45 to 90 with mild cognitive impairment or early dementia due to Alzheimer's disease, 20 weeks of the program against a wait-list usual-care control. Between-group differences on CGIC (p=0.001), CDR-SB (p=0.032) and CDR Global (p=0.037); ADAS-Cog borderline (p=0.053). The paper states raters were blinded to group; patients could not be. The program in this trial also included shipped meals and eight daily supplements (omega-3 with curcumin, a multivitamin, coenzyme Q10, vitamins C and B12, magnesium L-threonate, lion's mane and a probiotic), so it tests that whole package. Recruitment stopped at 51 for funding reasons, and the trial was registered after it began. One unreplicated trial: C.

CSurrogate biomarker PSA in early, low-grade prostate cancer on active surveillance

Ornish et al. (J Urol, 2005; PMID 16094059): 93 men with PSA 4 to 10 ng/mL and Gleason score under 7 who had chosen no conventional treatment; after 1 year PSA fell 4 percent on the program and rose 6 percent in controls (p=0.016), and 6 controls but no program patients started treatment. Frattaroli et al. (Urology, 2008; PMID 18602144): at 2 years, 13 of 49 controls and 2 of 43 program patients had started treatment, and PSA change no longer differed among untreated men. The decision to start treatment was made unblinded and is not a measure of the cancer itself. PSA is a surrogate, and one unreplicated trial: C.

DHard clinical endpoint · Not yet tested All-cause mortality and longevity

No randomized trial has tested the program against death from any cause or against lifespan. The Lifestyle Heart Trial (PMID 9863851) folded cardiac deaths into a combined count of cardiac events in 48 patients, far too few to measure mortality. Route 1 No human randomized trial has been run, so the record rests on animal or mechanistic evidence only. One of the two routes to the lowest letter on EBL's scale.: the trial has not been run.

Food
CHard clinical endpoint Grade C

Investigators: The single trial this Grade C for Coronary narrowing and cardiac events in coronary heart disease rests on was run by investigators employed by, founded by, or belonging to the organization that developed, sells or teaches the intervention (Dean Ornish, who developed the program and founded the Preventive Medicine Research Institute that teaches it). The funder may read non-commercial; the people who ran the trial are part of the organization whose intervention they tested, which is stated here so it can be weighed alongside the letter.

Funding: The single trial this Grade C for Cognition and function in mild cognitive impairment or early Alzheimer's disease rests on was funded by the maker of the studied product, who donated it. Funder's role, as reported: Ornish 2024 (PMID 38849944): the paper states the funders had no role in the design, data collection, analysis, interpretation or writing. The letter is what the trial supports under the grading rules; the funding is stated here so it can be weighed alongside it. Investigators: The single trial this Grade C for Cognition and function in mild cognitive impairment or early Alzheimer's disease rests on was run by investigators employed by, founded by, or belonging to the organization that developed, sells or teaches the intervention (the Preventive Medicine Research Institute, founded by Dean Ornish, which teaches the program). The funder may read non-commercial; the people who ran the trial are part of the organization whose intervention they tested, which is stated here so it can be weighed alongside the letter.

Investigators: The single trial this Grade C for PSA in early, low-grade prostate cancer on active surveillance rests on was run by investigators employed by, founded by, or belonging to the organization that developed, sells or teaches the intervention (the Preventive Medicine Research Institute, founded by Dean Ornish, which teaches the program). The funder may read non-commercial; the people who ran the trial are part of the organization whose intervention they tested, which is stated here so it can be weighed alongside the letter.

Coronary narrowing and cardiac events in coronary heart disease (C), cognition and function in mild cognitive impairment or early Alzheimer's disease (C), and PSA in early, low-grade prostate cancer on active surveillance (C). No randomized trial has tested the program against death (D). Every trial tested the whole program, so no letter applies to the diet by itself.

Why this letter

Why this gradeGrade C, small or unreplicated trials. The reasoning, and what the grade does not cover.
Why this grade

Grade C. Each use rests on a single small randomized trial run by the program's developers, and none has been repeated by an independent group. Coronary heart disease: the Lifestyle Heart Trial randomized 48 patients and reported slowed or reversed coronary narrowing at 1 and 5 years and 25 cardiac events in 28 program patients against 45 in 20 controls (Ornish et al., 1998; PMID 9863851). Cardiac events are a hard endpoint An outcome that matters directly to a person and is counted without judgment, such as death, heart attack, stroke or fracture., but the counts are events rather than patients, and they include angioplasty, bypass surgery and hospital admissions that unblinded doctors decided on. The one independent randomized trial of the program, against standard cardiac rehabilitation in 93 patients, found no change in carotid artery wall thickness (Aldana et al., 2007; PMID 17674638). Early Alzheimer's disease: one 20-week trial of 51 patients, with blinded raters, found better clinician-rated scores on three of four measures (Ornish et al., 2024; PMID 38849944). Prostate cancer: one trial of 93 men found a small PSA difference at 1 year (Ornish et al., 2005; PMID 16094059) that was not significant among untreated men at 2 years (Frattaroli et al., 2008; PMID 18602144).

WHY NOT Ba single unreplicated trial is Grade C by definition, whatever its endpoint The outcome a trial measures to decide whether the treatment worked, such as heart attacks, blood pressure or a symptom score..

WHAT THIS GRADE DOES NOT COVERthe diet on its own, which the trials never isolated; people without the diseases studied; mortality or longevity, graded D below; and less intensive versions of the program.

A grade describes the human evidence for a named use. It is not advice, and it is not a judgment on any individual prescription. How the letters are decided →

Who responds: this record's trial reading reports no subgroup that identifies who responds.

Evidence notes: randomized trial, not independently replicated

Endpoint graded: Cardiac events and coronary artery narrowing in coronary heart disease (hard)

Last reviewed: November 2026

Evidence wanted

The trial that would change this grade.

DesignRandomized trial of the full program against usual care or standard cardiac rehabilitation, run by at least two groups independent of the program's developers, with events adjudicated blind to group
PopulationAdults with coronary heart disease, at least 500 per arm
EndpointMyocardial infarction, stroke and cardiovascular death, counted per patient
DurationAt least 3 years

Positive trials of this shape from independent research groups would move this entry to A.

Why the current trials fall short

Every positive trial behind this record was run by the program's developers in under 100 patients. The one independent randomized trial measured carotid wall thickness and found no change.

Clinical trials

ClinicalTrials.gov, the public registry run by the U.S. National Library of Medicine, lists studies that are recruiting volunteers. The link below searches it for Ornish among studies recruiting now. EBL has no relationship with any listed study and receives no payment for this link.

Search recruiting studies of Ornish on ClinicalTrials.gov

Dose, form and timing

What to track

Measured outcomes in the trials: coronary artery narrowing on angiography at 1 and 5 years and cardiac events over 5 years in coronary heart disease; CGIC, CDR-SB, CDR Global and ADAS-Cog scores at 20 weeks in early Alzheimer's disease; PSA at 1 year in early prostate cancer. LDL Low-density lipoprotein cholesterol, the cholesterol fraction most closely tied to plaque in the arteries. cholesterol, body weight and blood pressure are the markers that moved with the program and can be read at baseline and after 3 to 12 months. Adherence to each part (diet, exercise, stress management, group support) is the process measure, since the trials tested them together.

As studiedDose, form, population and duration for every use.
As studied
FormThe whole program: a very low-fat whole-foods vegetarian diet (about 10 percent of calories from fat), aerobic exercise, stress management training, smoking cessation and group support (Ornish 1998, PMID 9863851); the same with a plant-based diet low in harmful fats, refined carbohydrates, alcohol and sweeteners, shipped meals, strength training and eight daily supplements (Ornish 2024, PMID 38849944).
DoseWhole-program pattern; in the Alzheimer's trial, three 4-hour sessions a week of supervised exercise, stress management, group support and a lifestyle lecture (Ornish 2024, PMID 38849944).
Population48 adults with moderate to severe coronary heart disease (Ornish 1998, PMID 9863851); 51 adults aged 45 to 90 with mild cognitive impairment or early dementia due to Alzheimer's disease (Ornish 2024, PMID 38849944); 93 men with early, low-grade prostate cancer on active surveillance (Ornish 2005, PMID 16094059).
Duration1 and 5 years (Ornish 1990, PMID 1973470; Ornish 1998, PMID 9863851); 20 weeks (Ornish 2024, PMID 38849944); 1 year with 2-year follow-up (Ornish 2005, PMID 16094059; Frattaroli 2008, PMID 18602144).
Coronary narrowing and cardiac events in coronary heart disease
FormVery low-fat whole-foods vegetarian diet, aerobic exercise, stress management training, smoking cessation and group support, against usual care
DoseWhole program, sustained for 5 years
Population48 adults with moderate to severe coronary heart disease
Duration1 and 5 years
Cognition and function in mild cognitive impairment or early Alzheimer's disease
FormPlant-based diet with shipped meals, aerobic and strength exercise, stress management, group support and eight daily supplements, against a wait-list usual-care control
DoseThree 4-hour sessions a week plus daily diet, exercise and supplements
Population51 adults aged 45 to 90 with mild cognitive impairment or early dementia due to Alzheimer's disease
Duration20 weeks
PSA in early, low-grade prostate cancer on active surveillance
FormVegan diet low in fat, moderate aerobic exercise, stress management and group support, against usual care
DoseWhole program for 1 year
Population93 men with early, low-grade prostate cancer on active surveillance
Duration1 year, with 2-year follow-up

A grade describes the intervention that was tested. Where the product on the shelf differs from it, this says so.

Safety

Cautions

No prominent contraindication A condition or medication that makes a treatment unsafe or unsuitable for a particular person. in the trials' reports. People with coronary heart disease in the trials exercised under a personal exercise prescription with medical oversight. The Alzheimer's trial version added eight daily supplements. People taking medicines for blood pressure, blood sugar or cholesterol can see those values fall when the diet changes.

Safety evidence, by strength

Cautions from mechanism only, no human harm data. Each caution on this record, sorted by what it rests on.

Documented in human studies
Cautions resting on what randomized trials or large studies found in people.

None recorded.

Suspected from case reports
Harms reported in individual patients or uncontrolled observations, not confirmed by a trial.

None recorded.

Mechanistic only
Cautions reasoned from how it works, with no human harm data behind them.
  • Drug interactions: blood pressure, blood sugar and cholesterol values can fall when the diet changes, in people taking medicines for them
Population cautions
Groups in whom it has not been studied, so its safety there is unknown.

None recorded.

No safety data

No safety data: EBL has found no trial or report of harm for this record. That is an absence of evidence, not a finding of safety.

Grade history

How this letter has changedLatest: No. 481 · November 2026 · First graded.
Grade history
No. 481 · November 2026 · First graded
Ornish Lifestyle Medicine enters the graded corpus at C

Ornish Lifestyle Medicine, the Ornish program, now has its own record, graded use by use after a PubMed search in November 2026. Coronary narrowing and cardiac events in coronary heart disease rest on one randomized trial of 48 patients run by the program's developers (Ornish et al., 1998; PMID 9863851); the one independent randomized trial of the program found no change in carotid artery wall thickness (Aldana et al., 2007; PMID 17674638): C. Cognition and function in early Alzheimer's disease rest on one 20-week trial of 51 patients that also gave eight daily supplements (Ornish et al., 2024; PMID 38849944): C. PSA in early prostate cancer rests on one trial of 93 men (Ornish et al., 2005; PMID 16094059): C. No randomized trial has tested death or longevity: D. Every trial tested the whole program, so no letter applies to the diet by itself. Applied the written grade definitions under the editor's standing instruction of October 2026 (Arnold Sandlow, D.C.).PMID 9863851 PMID 17674638 PMID 38849944 PMID 16094059

Every change to a letter on this site is dated and published. The full evidence log →

Sources

How this record was checked
Citations
Every paper cited on this page is matched to its PubMed record on every build.
Retractions
None of these papers is retracted or under a journal expression of concern. PubMed is checked again on every build.
Read against the papers
November 2026. By a language model (AI-assisted reading), not yet reviewed by a clinician.
Outside review
Not yet done. No reviewer outside EBL has checked this record.

What each of these checks can and cannot show: evidence integrity.

The evidence, in fullNine papers, each linked to its PubMed record.
The evidence

Coronary heart disease: Ornish et al. (Lancet, 1990; PMID 1973470): the Lifestyle Heart Trial, 28 patients assigned to the program and 20 to usual care; average diameter stenosis regressed from 40.0 to 37.8 percent on the program and progressed from 42.7 to 46.1 percent in controls after 1 year. Ornish et al. (JAMA, 1998; PMID 9863851): 5-year results of the same trial, 35 of 48 completing angiography; stenosis improved by 3.1 percentage points on the program and worsened by 11.8 in controls (P=.001); 25 cardiac events in 28 program patients against 45 in 20 controls (risk ratio 2.47 for controls, 95% CI 1.48 to 4.20). Gould et al. (JAMA, 1995; PMID 7674504): heart perfusion scans in the same trial's patients, 20 program and 15 control, improved on the program and worsened in controls. Aldana et al. (Am J Health Promot, 2007; PMID 17674638): an independent randomized trial, 93 patients with coronary artery disease, the Ornish program against traditional cardiac rehabilitation for 12 months; no significant change in carotid intima-media thickness in either group; diet, weight and angina improved more on the program. Early Alzheimer's disease: Ornish et al. (Alzheimers Res Ther, 2024; PMID 38849944): 51 patients with mild cognitive impairment or early dementia due to Alzheimer's disease, 26 to the program and 25 to a wait-list usual-care control for 20 weeks; between-group differences on the clinician-rated CGIC (p=0.001), CDR-SB (p=0.032) and CDR Global (p=0.037), borderline on the ADAS-Cog (p=0.053); raters blinded to group; meals were shipped to participants and the program included eight daily supplements; registered retrospectively (NCT04606420). Prostate cancer: Ornish et al. (J Urol, 2005; PMID 16094059): 93 men with early, low-grade prostate cancer (PSA 4 to 10 ng/mL, Gleason under 7) on active surveillance, randomized to the program or usual care for 1 year; PSA fell 4 percent on the program and rose 6 percent in controls (p=0.016); 6 control patients and no program patients started conventional treatment. Frattaroli et al. (Urology, 2008; PMID 18602144): 2-year follow-up of the same trial; 13 of 49 controls and 2 of 43 program patients had started conventional treatment; no significant PSA difference between untreated patients at 2 years. The diet alone: Dansinger et al. (JAMA, 2005; PMID 15632335): 160 overweight adults randomized to the Atkins, Zone, Weight Watchers or Ornish diet; 1-year weight loss 3.3 kg on Ornish, similar to the others, and weight loss tracked adherence, not diet type. Gardner et al. (JAMA, 2007; PMID 17341711): 311 overweight premenopausal women; 12-month weight loss 2.2 kg on Ornish against 4.7 kg on Atkins, not different from Zone or LEARN. Funding: the Lifestyle Heart Trial (National Heart, Lung, and Blood Institute) and the prostate trial (National Cancer Institute) were government and foundation funded and run by the program's developers; the Alzheimer's trial was funded by foundations and donors, with food, supplements and exercise equipment donated by their makers, and run by the program's developers with outside collaborators.

How EBL searched for the trials (1 search)

The search that was run, what it returned, and what was left out and why, so the absence of evidence can be checked as well as its presence.

Searched PubMed in November 2026. 22 records screened, 9 eligible for the graded claim.
Query: (Ornish[tiab] OR "Lifestyle Heart Trial"[tiab] OR "intensive lifestyle changes"[tiab] OR "comprehensive lifestyle changes"[tiab]) AND randomized controlled trial[pt]
Randomized trials of the Ornish program, or of the Ornish diet alone. Eligible and cited: the Lifestyle Heart Trial (PMID 1973470, PMID 9863851, PMID 7674504), the independent Aldana trial (PMID 17674638), the Alzheimer's trial (PMID 38849944), the prostate trial (PMID 16094059, PMID 18602144), and the two independent diet-only comparisons (PMID 15632335, PMID 17341711). Excluded: the Women's Lifestyle Heart Trial (PMID 10892523, 28 women, under the 30-participant floor), secondary analyses of the prostate trial (PMID 17571965, PMID 16413347, PMID 11295627), other lifestyle programs that are not the Ornish program (Mediterranean Lifestyle Program, U-TURN, an insulin-sensitivity trial, a German rehabilitation pilot, a Maori diabetes pilot), A TO Z secondary analyses, and a dietary assessment trial.
PubMed watch: does a new study change the grade? (nothing new)

No new paper matching the search behind this grade has been added to PubMed since November 2026.

Last run November 2026. A letter on EBL moves only after a logged review. A new paper never moves a letter by arriving: it is read, the answer is written here, and any change to the letter is published in the evidence log.

Who paid for these trials

For each trial behind a letter on this page, the funding its PubMed record lists. "No funder" means PubMed lists none, not that the trial had no funding.

  • Ornish et al., 1998, JAMA (PMID 9863851): PubMed lists funding from US National Institutes of Health (National Heart, Lung, and Blood Institute).
  • “Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial” (PMID 1973470): PubMed lists funding from US National Institutes of Health (National Heart, Lung, and Blood Institute).
  • “Changes in myocardial perfusion abnormalities by positron emission tomography after...” (PMID 7674504): PubMed lists funding from US National Institutes of Health (National Heart, Lung, and Blood Institute).
  • “The effects of an intensive lifestyle modification program on carotid artery...” (PMID 17674638): PubMed lists no funder for this trial.
  • “Effects of intensive lifestyle changes on the progression of mild cognitive impairment...” (PMID 38849944): PubMed lists funding from US National Institutes of Health (National Institute on Aging); Alzheimer Gut Microbiome Project; The Alzheimer's Drug Discovery Foundation. The PubMed record carries a competing-interest statement.
  • “Intensive lifestyle changes may affect the progression of prostate cancer” (PMID 16094059): PubMed lists funding from US National Institutes of Health (National Cancer Institute).
  • “Clinical events in prostate cancer lifestyle trial: results from two years of follow-up” (PMID 18602144): PubMed lists funding from US National Institutes of Health (National Cancer Institute); PHS HHS.
  • “Comparison of the Atkins, Ornish, Weight Watchers, and Zone diets for weight loss and...” (PMID 15632335): PubMed lists funding from US National Institutes of Health (National Heart, Lung, and Blood Institute); US National Institutes of Health (National Center for Research Resources); US National Institutes of Health (National Institute of Diabetes and Digestive and Kidney Diseases); AHRQ HHS.
  • “Comparison of the Atkins, Zone, Ornish, and LEARN diets for change in weight and...” (PMID 17341711): PubMed lists funding from US National Institutes of Health (National Center for Research Resources); US National Institutes of Health (National Center for Complementary and Integrative Health).

Disclosure

Educational use only · Not medical advice · EBL grades published human evidence and does not recommend treatment. Stopping a prescription is a decision for your physician.

Evidence Based Longevity, Inc. is owner-operated and edited by Arnold Sandlow, D.C., a California-licensed chiropractor. Evidence Based Longevity publishes in English only · Machine translations are not produced or reviewed by EBL for accuracy

© Evidence Based Longevity, Inc. All rights reserved

Medical disclaimer

These statements have not been evaluated by the Food and Drug Administration. Any grade on this page describes the strength of published human trial evidence in the populations studied. It is not a recommendation for any individual and is not medical advice. Starting, stopping or changing any supplement or medication is a decision for your physician.

Grades move when new trials publish. A free monthly email lists every grade EBL moved, with the reason and the trial behind it: the sign-up is on the Evidence Log →

Build 9b19d78, November 2026